

Expanding Use of cfDNA Screening in Pregnancy: Current and Emerging Ethical, Legal, and Social Issues

Lindsay Parham¹ · Marsha Michie² · Megan Allyse³

Published online: 11 February 2017
© Springer Science + Business Media New York 2017

Abstract

Purpose of Review In 2011, screening platforms became available in the US that detect and analyze fragments of cell-free placental DNA (cfDNA) in maternal blood serum. Marketed as noninvasive prenatal tests (NIPT), cfDNA screening is more accurate than previously available serum screening tests for certain aneuploidies. The combination of a noninvasive procedure, high specificity and sensitivity, and lower false positive rates for some aneuploidies (most notably Down's syndrome) has led to broad clinician and patient adoption. New ethical, legal, and social issues arise from the increased use and expanded implementation of cfDNA in pregnancy.

Recent Findings Recently, several professional associations have amended their guidelines on cfDNA, removing language recommending its use in only “high-risk” pregnancies in favor of making cfDNA screening an available option for women with “low-risk” pregnancies as well. At the same time, commercial cfDNA screening laboratories continue to expand the range of available test panels. As a result, the future of prenatal screening will likely include a broader range of genetic tests in a wider range of patients.

Summary This article addresses the ethical, legal, and social issues related to the shift in guidance and expanded use of

cfDNA in pregnant women, including concerns regarding routinized testing, an unmet and increasing demand for genetic counseling services, social and economic disparities in access, impact on groups living with disabling conditions, and provider liability.

Keywords cfDNA · Prenatal screening · NIPT · Ethics · Legal issues · Social issues

Introduction

Prenatal genetic screening and testing are a common element of obstetrical care in the United States (US). Genetic screening and testing typically are conducted for congenital conditions associated with genetic anomalies, most commonly chromosomal aneuploidy. Screening tests use low-risk and noninvasive techniques, such as a blood sample or ultrasound, to identify fetuses with elevated risks for congenital conditions [1, 2]. However, screening procedures have a false positive rate of up to 15%, depending on the combined protocol used [2–4]. Prenatal diagnostic tests include more invasive procedures that collect amniotic fluid (amniocentesis) or placental tissue (chorionic villae sampling, “CVS”) and can provide definitive results based on analysis of amniotic or placental DNA [5]. Diagnostic procedures are generally elected by pregnant women considered to be at higher risk for carrying a fetus with genetic condition: those over 35 years of age at delivery, with a family history of certain genetic conditions, screen-positive results, or a previously affected birth [6]. Invasive procedures carry a small risk of infection or miscarriage (less than 1 in 300 to 500 when performed by a well-trained clinician) [6].

In 2011, screening platforms became available in the US that detect and analyze fragments of cell-free placental DNA (cfDNA) in maternal blood serum. Marketed as noninvasive

This article is part of the Topical Collection on *Ethics in Genetic Medicine*

✉ Megan Allyse
Allyse.Megan@mayo.edu

¹ School of Law, Department of Jurisprudence and Social Policy, University of California, Berkeley, Berkeley, CA, USA

² School of Nursing, Institute for Health and Aging, University of California, San Francisco, San Francisco, CA, USA

³ Biomedical Ethics, Mayo Clinic, Rochester, MN, USA

prenatal tests (NIPT), for certain aneuploidies, cfDNA screening is more accurate than previously available serum screening tests: sensitivity and specificity for Trisomy 21 (Down syndrome) is reported as above 99% with less than 1% false positive rates [7, 8, 9, 10–12]. However, sensitivity and specificity vary significantly depending on the condition, and test performance is lower for all other aneuploidies that the test platforms cover [13]. Test panels typically offer results on the three most common aneuploidies (trisomies 13, 18, and 21) and sex chromosome anomalies, including Turner and Klinefelter syndrome; further, as of 2015, some test panels include selected microdeletions.

As of 2015, many professional societies—including the National Society of Genetic Counselors (NSGC), the International Society for Prenatal Diagnosis (ISPD), the Society for Maternal-Fetal Medicine (SMFM), and the American Congress of Obstetricians and Gynecologists (ACOG)—had recommended that cfDNA screening be offered only to women at higher risk for fetal aneuploidy, include only the three most common aneuploidies, and include pretest and posttest counseling [14, 15, 16, 17]. However, in 2016, SMFM and ACOG amended their guidelines to say that cfDNA screening could be offered to any woman who expressed a need for information beyond serum screens [18]. In 2016, the American College of Medical Genetics and Genomics (ACMG) also amended its guidelines to recommend that cfDNA screening for common trisomies should be offered in all pregnancies, provided that adequate counseling, decisional support, and test reporting procedures were in place [19]. It also advised that expanded screening for sex chromosome aneuploidies and microdeletions should be used cautiously, and with careful attention to the higher false positive and lower positive predictive value of these screens. At the same time, commercial cfDNA screening laboratories continue to expand the range of available test panels. In 2016, Sequenom announced that it would begin offering a “genome-wide” cfDNA screen to detect copy number variants of 7 megabase pairs (Mbp) or larger [20]. Researchers at the University College of London began offering cfDNA screening for single gene disorders, including sickle cell disease and achondroplasia [21]. It seems clear that the future of prenatal care will include a broader range of genetic tests in a wider range of patients. Here, we discuss the social, ethical, and legal issues related to this shift.

Ethical and Clinical Issues

Informed Consent and Routinization

One common concern about prenatal cfDNA screening is that it may increase routinization of prenatal genetic testing and erode informed consent processes [22, 23, 24, 25–29]. Routinization, a process in which a biomedical innovation is

transformed into routine medical practice, decreases attention to decision-making processes among both providers and patients [30, 31]. Routinization has been well documented in other forms of prenatal screening and testing [30, 32, 33]. cfDNA screening, at least partially due to its ease of use and procedural similarity to serum screening, has quickly become part of prenatal clinical routines [34]. Some scholars issued early warnings that these characteristics might also mean that pretest counseling and informed consent for cfDNA screening would resemble the routine description and acceptance of serum screens [35, 36], and these warnings appear to have been borne out. Certainly, early studies suggest that cfDNA screening receives considerably less counseling and decision-making attention than diagnostic procedures, even as the information load available from such screening expands toward that of diagnostic procedures [23, 27, 37, 43]. Even when written informed consent is sought, informed consent documentation for cfDNA screening frequently lacks attention to recommended elements of consent—including descriptions of the conditions being screened and the possibility of inaccurate results—and rarely meets readability standards [38].

Provider and Patient Information

Concerns about informed consent go hand-in-hand with those about the education and informational materials provided to both patients and health care providers. Only recently have academic, nonprofit, and professional organizations begun disseminating educational tools and materials for providers about cfDNA screening.¹ Many clinicians have reported that cfDNA screening companies provided the majority of the information they received about cfDNA screening, via marketing materials, websites, educational seminars, and direct outreach [34, 39]. Companies also aggressively market to pregnant women and families through online advertising, participation in online pregnancy discussion boards, and print materials at clinical offices and elsewhere [40–43]. These online and print marketing materials have been assessed by researchers and neither meet readability standards for patient information materials nor offer all information about cfDNA screening recommended by professional organizations [41–43].

Little is yet known about the quality of provider knowledge and education regarding cfDNA screening. A survey of

¹ These currently include the NIPT/Cell Free DNA Predictive Value Calculator, from the Perinatal Quality Foundation and the National Society of Genetic Counselors (NSGC) and endorsed by the American Congress of Obstetricians and Gynecologists (ACOG) (<https://www.perinatalquality.org/Vendors/NSGC/NIPT/>); an Abnormal Prenatal Cell-free DNA Screening Results fact sheet from NSGC, endorsed by ACOG (<http://nsgc.org/page/abnormal-non-invasive-prenatal-testing-results>), and a cfDNA Policy “Cliff’s Notes” chart by the Genetic Support Foundation (<https://www.geneticsupportfoundation.org/providers/cfDNA-for-providers>).

maternal-fetal medicine fellows conducted in 2012 found that nearly all respondents (97%) understood that cfDNA was non-diagnostic, but only 35% knew all validated indications [39]. While a majority of respondents reported that they learned about cfDNA screening from formal educational activities, self-review of literature, and discussions with peers, many also reported receiving information from commercial laboratory representatives (31%) and laboratory-produced materials (22%) [39]. Among frontline providers (including obstetricians, nurse practitioners, certified nurse-midwives, and family medicine specialists), an earlier survey of obstetricians found that nearly half mistook cfDNA as essentially diagnostic [44], though it must be noted that little professional guidance had been issued at the time of that survey. A more recent survey of obstetricians and certified nurse-midwives found significant gaps in knowledge and comfort with counseling about first-trimester serum screening, including aneuploidy risk and posttest reproductive options, topics that are equally important in cfDNA screening [45]. Gaps in the knowledge of these frontline prenatal healthcare providers are concerning, since a recent survey of obstetricians found that 83.3% offered prenatal genetic screening of some type, 59.6% served as patients' primary pretest counselor, 43.9% counseled patients on screen-positive results, and only 30% referred screened patients with positive results to a genetic counselor [46]. More research is needed on provider education and counseling for prenatal cfDNA screening, particularly among frontline providers.

Increased Use in Low-Risk Populations

In 2014, commercial cfDNA companies began to release sponsored academic research that suggested the sensitivity and specificity of cfDNA screening for major trisomies was comparatively high in both over 35 and general populations [47]. These findings suggested that cfDNA screening might be expanded for use in a general obstetric population, and in 2016, the American College of Medical Genetics' Noninvasive Prenatal Screening Work Group amended its guidelines accordingly (see above) [19]. Clinical uptake is still uncertain, but in a 2016 study, 8 of the 19 insurance payers examined had extended coverage of cfDNA screening to an average risk population, citing professional guidelines [48•]. This development suggests that professional guidance and payer practice are beginning to align in introducing the option of cfDNA screening to most covered pregnancies. However, the uptake by state Medicaid programs remains uneven; due to the patchwork nature of pregnancy care coverage among Medicaid plans, tracking coverage for screening can be difficult.

One of the most problematic elements of this expansion into general populations is the impossibility of providing specialty counseling and interpretation services to every woman

considering prenatal screening and testing. Historically, women at higher risk of a pregnancy affected by a genetic condition were referred to maternal-fetal medicine or genetic counseling services. However, maternal-fetal medicine practices are generally restricted to tertiary care centers, and there are a strictly limited number of certified prenatal genetic counselors to counsel patients. Due to broad difficulties in receiving reimbursement for genetic counseling services, the majority of general practices cannot afford a full time genetic specialist [49, 50]. As a result, frontline providers will increasingly be responsible for discussing screening and testing options and delivering results of prenatal genetic screens. Due to limitations on time and reimbursement, these practitioners often find it challenging to stay abreast of rapidly evolving genetic screening options, let alone adequately counsel patients about the increasing number of genetic conditions for which cfDNA screening is offered [34].

Expansion of Test Content

Concerns about expanding use of cfDNA screening in the general obstetric population increase with continual expansion of test panel content to include sex chromosome anomalies (SCA) like monosomy X (Turner syndrome) and Klinefelter syndrome; some microdeletions and subdeletions like 22q11.2 (DiGeorge syndrome) and Prader-Willi syndrome; and (on one panel) genome-wide copy number variants of 7 Mbp or larger and certain deletions that are smaller than 7 Mbp [20•].

Since any test's positive predictive value (PPV) depends on the population incidence of the condition tested, the PPV of cfDNA screening for trisomy 21 in higher-risk pregnancies remains high [51]. However, the PPV for rarer trisomies is lower, and is quite low for very rare conditions in a low-risk pregnancy, for instance between 2 and 4% PPV for the most common cfDNA-screened microdeletion, 22q11.2 (DiGeorge syndrome) [51]. As more and rarer conditions are added, inconclusive cfDNA screening results may necessitate increased follow-up testing, thus negating the reduction in invasive procedures that makes cfDNA screening appealing. Despite concerns about PPV, initial data on use of cfDNA screening indicates that it has led to a reduction in invasive follow-up procedures, with numbers of invasive procedures in California dropping from 47.2% from the year before cfDNA screening was introduced to 39.2% afterward [52]. A decrease in invasive diagnostic testing is a positive development but may also be cause for concern, as it may make it more difficult to train practitioners in techniques like amniocentesis and CVS or to keep practitioners' skills up-to-date. Finally, expanded test content presents challenges for genetic counselors and other practitioners, who must be vigilant to stay well informed about new test panels and to evaluate the clinical data available for

each new result being offered so that counseling can be thorough and accurate.

Social Issues

Trends in Prenatal Screening and Termination of Affected Pregnancies

Expansions in the scope of cfDNA screening and population being offered it also have potential downstream effects socially and ethically. Several observers have raised concerns that the expansion of universal cfDNA screening will increase the number of abortions; this concern is exacerbated by existing evidence of diagnostic misconceptions among both patients and nonspecialist providers [53–55].

Another concern with expanded panels is the introduction of population-level screening for conditions that have not, historically, been the target of screening. In the US, sex chromosome aneuploidies have generally been identified in the neonatal period, if they are diagnosed at all, and many individuals with milder phenotypes are never diagnosed [56]. The introduction of cfDNA screening for these conditions, along with a high rate of false positive results, is forcing a rapidly expanding number of families and providers to confront difficult decisions about diagnostic testing and pregnancy continuation.

It is too early in the expansion of cfDNA to ascertain the impact this expansion will have on termination rates for these new conditions. Although numbers vary widely by geographic region, the historic US average rate of elective termination after a prenatal trisomy 21 diagnosis is approximately 61%, resulting in an estimated 20% decrease in live births of individuals with Down syndrome [57]. Existing data on parental decision-making following a diagnosis of sex chromosome aneuploidy indicates variation by condition but suggests an elective termination rate of 61–85% [58]. Even if the *rate* of terminations does not change with the introduction of cfDNA, its higher sensitivity and increasing popularity mean that more families will likely be offered such decisions. Thus, concern that the absolute number of terminations will increase may be realized.

Perspectives Regarding Disabilities

The high rate of elective terminations after a prenatal diagnosis may be partly due to a lack of understanding of genetic conditions and their impact on families. Indeed, a major component of the “disability critique” is that prenatal testing itself “depends on a misunderstanding of what life with a disability is like” [59]. Phenotypes of prenatally tested genetic conditions range from very mild to fatal; people considering whether to have prenatal testing or considering test results may have

difficulty distinguishing a particular condition from this wide range of possible outcomes [32, 33, 60, 61]. Information regarding individual and family quality of life may be poor, and counseling to help families parse the available information is often scarce [62–66]. However, past studies of families that include individuals with Down syndrome, for example, have shown both that individuals with Down syndrome and their families generally report happiness and high quality of life, and that reported problems tended to be due to external factors like prejudice rather than the condition itself [67–70]. Significant improvements in medical care and social support services have also significantly changed the profile of living with many genetic conditions, in terms of both length and quality of life [66, 71–73].

Many scholars have also expressed concerns that prenatal cfDNA screening will erode social support for families with genetic conditions [28, 74–76]. Such concerns have been expressed about prenatal testing for decades, and there is some evidence that public attitudes toward those with prenatally detectable conditions have been shaped by the ability to predict and prevent their birth [26, 77–79, 80, 81]. However, some families with genetic conditions have also expressed support for prenatal testing, often maintaining that prenatal information can help families prepare for a wanted child, who has special needs [74, 81–84].

Equity in Access

As cfDNA screening rapidly expands, disparities in access are another concern. As a commercial product, the cost of cfDNA panels is at the discretion of commercial laboratories that offer the test. Traditional serum screening and ultrasound protocols in the US are widely provided or reimbursed through states’ Departments of Health and/or Medicaid programs, and there is rarely a significant out of pocket cost to the patient [85]. By contrast, as of 2016, cfDNA screening was only gradually gaining acceptance and reimbursement by many private group insurance providers. Among public programs, California is the only US state to include cfDNA panels in a state prenatal screening program and then only as a contingent screen after other screen-positive results [86]. For the majority of its clinical use, therefore, cfDNA screening has mainly been available as an out of pocket expense, although in some instances, insurance companies will subsidize its use [87, 88]. Inevitably, this leads to improved access to cfDNA screening among patients with more comprehensive insurance coverage and/or higher income [89, 90]. Moving forward, it is not at all clear that either public or private payers in the US will find it cost-effective to offer universal coverage of cfDNA screening as a first-tier screen. Recent comprehensive analyses in the Canadian and UK health systems found that cfDNA screening offered cost savings when used as a contingent screen—that is, to follow up on high-risk serum screens—but not as a first-

tier test [91•, 92]. For those without preexisting risk indicators, therefore, cfDNA is likely to remain a not insignificant out-of-pocket cost for the foreseeable future.

The creation of a “two-tier” health care system, in which higher standards of care are offered to those who can pay for them, is considered fundamentally unjust by many, and as perpetuating and exacerbating existing disparities in health, quality of life, and lifespan [93, 94]. Furthermore, those with lower socioeconomic status are likely to have considerably fewer resources to fully support a pregnancy and/or child with a genetic condition. The advantages afforded by earlier genetic screening are arguably higher in these populations, if they can utilize screening to access them. At the same time, increased preoccupation with newer screens is in danger of occluding the resources and support services devoted to the traditional screening protocols that disproportionately continue to serve individuals from lower socioeconomic groups. Moreover, when high-risk results are returned, it seems clear that those with private insurance will more readily enjoy improved access to follow-up care—including counseling, diagnostic testing, and social support services—than those from other groups [90, 95, 96, 97•, 98•]. The question of how and where to devote the public health resources necessary to adequately support the broad expansion of cfDNA panels and patient populations is one of the defining challenges of the translation of this technology.

Legal Issues

Intellectual Property

The technology underlying cfDNA screening has all been patented, which creates a complex patent landscape in the US. Over 100 patents have been filed regarding cfDNA screening technology, and the first four companies to enter the US market have engaged in numerous legal battles over the past several years to control access to the market [99•]. Several cases have centered on Sequenom’s 2011 patent on the method of detecting maternal cfDNA commonly used in cfDNA screening [100]. The validity of the patent was only recently decided when the Supreme Court refused to hear Sequenom’s appeal of a 2013 Federal Court ruling the patent invalid [100]. This decision may bring some stability to the volatile IP environment around cfDNA screening and also addresses issues of monopoly that a successful suit by Sequenom might have created. However, the significant costs of such lawsuits may be passed on to consumers as companies try to recoup costs. Additionally, the intellectual property landscape is shifting as several companies, including Sequenom and Natera, pool their patents and license them out to independent labs. At least 46 labs have so far taken licenses using this underlying intellectual property [99•].

Regulatory Oversight

cfDNA screening platforms have been marketed by manufacturers as “laboratory developed tests” (LDTs), which means laboratories are monitored by the Centers for Medicaid Services under the Clinical Laboratory Improvement Amendments (CLIA) act. In 2014, the Federal Drug Administration (FDA) announced a draft guidance that would extend FDA oversight to more strictly cover “moderate” or “high-risk” LDTs, which would include cfDNA screening platforms [101]. As of publication, such regulations are yet to be finalized [101]. Under the current regulatory oversight, CLIA monitoring does not directly address patient safety concerns because CLIA neither assesses the clinical validity of tests nor validates tests prior to entering the market [102].

Abortion and Reproductive Rights: Return of Genetic Disability and Fetal Sex Information

cfDNA screening use may increase women’s reproductive options and improve maternal safety in cases where a woman chooses to terminate her pregnancy. Because cfDNA screening can be used as early as 9–10 week’s gestation, women may receive their results as early as 11–12 weeks. This is far earlier than traditional blood serum screens or amniocentesis results, many of which are not available until 15–20 week’s gestation. While professional societies do not recommend using cfDNA screening as a diagnostic tool, screen results may enable patients and providers to schedule diagnostic tests earlier in a pregnancy [103]. In states like Arizona, Arkansas, Nebraska, and Texas (among others) where legislation restricts women’s access to abortion prior to viability—in some cases as early as 20 weeks [104]—this may increase the amount of time a woman has to access abortion services. Earlier termination increases maternal welfare; complications associated with abortion, while very rare, increase with each week gestation [105].

However, some states are restricting abortion on the basis of termination for fetal sex or genetic disability, including Indiana, South Dakota, and Ohio [104]. The enforcement mechanism for these laws is questionable, as is their constitutionality, and Indiana’s law was blocked in a Federal District Court because it limits access to abortion prior to viability [106]. However, clinicians must be aware of their state’s laws regarding termination on the basis of genetic information.

Physician Liability

As cfDNA screening becomes more common in clinical care and expands into lower-risk populations of pregnant women, concerns about legal liability for healthcare providers also increase. Charges of medical negligence may arise if a physician does not meet the standard of care in genetic testing,

resulting in a missed or incorrect diagnosis [107]. As cfDNA screening and its use change rapidly, gaps often develop between tests' advertised capabilities, professional recommendations, and actual clinical use in a given geographic area, leading to uncertainties regarding standards of care and legal obligations [108]. As cfDNA screening technology moves into general practice, the legal obligations of clinicians without specialized training in genetics similarly become unclear. A medical negligence claim in this area may derive from omission or incorrect information given to a patient or from not properly explaining the potential error in genetic results from testing, both circumstances that may increase with increased use of cfDNA screening in nonspecialized, general practices [107, 109]. To date, no successful case regarding medical negligence and cfDNA screening has occurred, but as with all new medical technologies, as the use of cfDNA screening becomes more widespread, the likelihood increases for medical negligence cases to be brought [109].

Conclusion

cfDNA screening technologies continue to advance internationally. In 2016, the Wellcome Trust Sanger Institute in the UK announced a consortium to carry out the Prenatal Assessment of Genomes and Exomes; including the sequencing, via cfDNA, of over 1000 families for which a structural abnormality has been detected by ultrasound, with an eye toward clinical translation [110]. The Chinese University of Hong Kong announced that cfDNA screening could detect not only the presence of malignancy in the maternal sample but also the organ system implicated, potentially bringing us closer to a liquid biopsy in oncology care [111]. Meanwhile, the same lab reported that they had advanced methods of detecting methylation status and size of DNA fragments to make cfDNA screening even more specific and expand its potential applications to the detection of thalassemia disorders [112]. Given that thalassemia disorders are the most common genetic disorders in humans—an estimated 307,900 children are born annually with a severe hemoglobin disorder—the ability to initiate noninvasive population screening for these disorders may constitute a much greater public health benefit than the comparatively rarer conditions currently screened [113]. Finally, in late 2016, Jain et al. published a study reporting the success of a method of performing cfDNA screening on trophoblast cells retrieved from the endocervical canal [114]. If validated, this technique may in the future extend the timeline of cfDNA back as early as 5 weeks gestation.

These unprecedented expansions into the scope and abilities of cfDNA screening offer the potential for enormous clinical benefit, especially as research on the future

of prenatal interventions to address genetic abnormalities continues to move forward [115]. However, the rapid progress of the technology is straining the available resources for counseling and interpretation of results, and this trend is likely to continue as the number of individuals in the US and worldwide who are offered cfDNA screening continues to grow [23•]. This strain is even more prevalent in low-resources areas, including rural areas in both the US and abroad [116], raising the specter of a large number of women receiving screening on an uninformed basis and/or receiving or making incorrect interpretation of results, potentially leading to pregnancy termination they would not seek if provided accurately interpreted results and genetic counseling. It also raises the very pertinent question of the impact this widespread screening will have on the balance of social forces around wellness, maternal responsibility, and disability [26, 78, 117–120]. As more and more screening for an increasingly broad swath of the genome continues to take hold, it is realistic to assume that the concept of what it means to have a “healthy” fetus must evolve; at a broad enough level of sequencing, *all* individuals contain genetic variants of unknown impact on the phenotype.

Meanwhile, there are difficult resource allocation decisions to be made about the best way to extend our health care energies in the prenatal period. There are strong arguments to be made that, given uneven access to basic obstetric services, it is inappropriate to continue expansion of a highly technocratic technology with unproven clinical utility [96, 121, 122]. Both public and private health insurers, providers, and policy-makers will need to grapple with the appropriate support for such a new and rapidly developing technological protocol. As discussed, there are likely to be considerable legal and policy implications of both cfDNA's presence in prenatal care protocols and the downstream effects of our ever-growing knowledge of fetal genomic information. It remains essential to maintain a robust research agenda around the legal, public health, social justice, and psychosocial impact on the expansion of cfDNA screening on women, families, and health systems as a whole. The future of cfDNA screening is promising, but it is not yet an uncomplicated good.

Acknowledgements This paper was funded in part by the National Institutes of Health (Grant R00HG006452: Michie).

Compliance with Ethical Standards

Conflict of Interest The authors each declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. *Obstet Gynecol.* 2007;109(1):217–27.
- Simpson JLS, Holzgreve W, Driscoll DA. Chapter 10: Genetic counseling and genetic screening. In: Gabbe SG, Niebyl JN, Simpson JLS, Landon ML, Galan HG, Jauniaux EJ, Driscoll DD, editors. *Obstetrics: normal and problem pregnancies*. Philadelphia: Elsevier/Saunders; 2012b.
- Benn PA, Ying J, Beazoglou T, Egan JF. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. *Prenat Diagn.* 2001;21(1):46–51.
- Cuckle HS, Malone FD, Wright D, Porter TF, Nyberg DA, Comstock CH, et al. Contingent screening for Down syndrome—results from the faster trial. *Prenat Diagn.* 2008;28(2):89–94.
- Simpson JLS, Richards D, Otaño L, Driscoll DA. Chapter 11: Prenatal genetic diagnosis. In: Gabbe SG, Niebyl JN, Simpson JLS, Landon ML, Galan HG, Jauniaux EJ, Driscoll DD, editors. *Obstetrics: normal and problem pregnancies*. Philadelphia: Elsevier/Saunders; 2012c.
- ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: invasive prenatal testing for aneuploidy. 00006250-200712000-00050.pdf 2007; 88:1459–67.
- Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. *American Journal of Obstetrics & Gynecology.* 2012;206(4):322.e1–5.
- Ashoor G, Syngelaki A, Wang E, Struble C, Oliphant A, Song K, Nicolaides KH. Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. *Ultrasound Obstet Gynecol.* 2013;41(1):21–5.
- Bianchi D, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med.* 2014;370:799–808. **Published online. Concludes that in a general obstetrical population, prenatal testing with the use of cfDNA had significantly lower false positive rates and higher positive predictive values for detection of trisomies 21 and 18 than standard screening**
- Mazloom AR, Džakula Ž, Oeth P, Wang H, Jensen T, Tynan J, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. *Prenat Diagn.* 2013;33(6):591–7.
- Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. *Prenat Diagn.* 2013;33(6):575–9.
- Willems PJ, Dierickx H, Vandenakker E, Bekedam D, Segers N, Deboulle K, Vereecken A. The first 3,000 non-invasive prenatal tests (NIPT) with the harmony test in Belgium and the Netherlands. *Facts Views Vis Obgyn.* 2014;6(1):7–12.
- Baer RJ, Currier RJ, Norton ME, Flessel MC, Goldman S, Towner D, Jelliffe-Pawlowski LL. Obstetric, perinatal, and fetal outcomes in pregnancies with false-positive integrated screening results. *Obstet Gynecol.* 2014;123(3):603–9.
- The American College of Obstetricians and Gynecologists Committee on Genetics, The Society for Maternal-Fetal Medicine Publications Committee. Committee Opinion number 545: noninvasive prenatal testing for fetal aneuploidy. *Obstet Gynecol.* 2012; doi:10.1097/01.AOG.0000423819.85283.f4.
- Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B, et al. Position statement from the aneuploidy screening committee on behalf of the board of the international society for prenatal diagnosis. *Prenat Diagn.* 2013;33(7):622–9.
- Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, Borry P, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. *Eur J Hum Genet.* 2015;23:1438–50. **Joint European Society for Human Genetics and American Society for Human Genetics statement recommending a cautious expansion of the scope of prenatal screening to serious congenital and childhood disorders, and an active role of government in ensuring responsible innovation and use of NIPT in countries where prenatal screening is offered as a public health program**
- Wilson KL, Czerwinski JL, Hoskovec JM, Noblin SJ, Sullivan CM, Harbison A, et al. NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. *J Genet Couns.* 2013;22(1):4–15.
- ACOG and SMFM. Ob-Gyns release revised recommendations on screening and testing for genetic disorders. Press Release 2016.
- Gregg AR, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med* 2016.
- Lefkowitz RB, Tynan JA, Liu T, Wu Y, Mazloom AR, Almasri E, et al. Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. *Am J Obstet Gynecol.* 2016;215:227. **Demonstrates that in pregnancies at an increased risk for fetal chromosomal abnormalities, genomewide NIPT for fetal chromosomal abnormalities can provide high resolution, sensitive, and specific detection of a wide range of subchromosomal and whole chromosomal abnormalities that were previously only detectable by invasive karyotype analysis**
- Verhoef TI, Hill M, Drury S, Mason S, Jenkins L, Morris S, Chitty LS. Non-invasive prenatal diagnosis (NIPD) for single gene disorders: cost analysis of NIPD and invasive testing pathways. *Prenat Diagn.* 2016;36:636–42. **Evaluates the costs of offering non-invasive prenatal diagnosis (NIPD) for single gene disorders compared to traditional invasive testing; finds that NIPD may be less expensive than invasive testing for some disorders, but may be higher for others, suggesting increased uptake of NIPD will become a major contributing factor to the cost of a genetic service for prenatal diagnosis in clinical practice**
- Michie M, Allyse M. Old questions, new paradigms: ethical, legal, and social complications of noninvasive prenatal testing. *AJOB Empirical Bioethics.* 2015;6(1):1–4.
- Mozerksy J. Hoping someday never comes: deferring ethical thinking about noninvasive prenatal testing. *AJOB Empirical Bioethics.* 2015;6(1):31–41. **Observational study highlights the ethical continuities between NIPT and other forms of prenatal screening and testing including deferring decision-making regarding test results; the continued expansion of screening to include more women and conditions will increase the number of women who receive positive results and may be shocked and unprepared as a result**
- de Jong A, de Wert GM. Prenatal screening: an ethical agenda for the near future. *Bioethics.* 2015;29(1):46–55. **Assesses the ethical justifications of prenatal screening, particularly as test capacities develop, with an emphasis on the extent they contribute to**

- or undermine the stated aim of providing meaningful options for reproductive choice**
25. Deans Z, Clarke AJ, Newson AJ. For your interest? The ethical acceptability of using non-invasive prenatal testing to test 'purely for information'. *Bioethics*. 2015;29(1):19–25.
 26. Kaposy C. A disability critique of the new prenatal test for Down syndrome. *Kennedy Inst Ethics J*. 2013;23(4):299–324.
 27. van den Heuvel A, Chitty L, Dormandy E, Newson A, Deans Z, Attwood S, et al. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. *Patient Educ Couns*. 2010;78(1):24–8.
 28. Lewis C, Silcock C, Chitty LS. Non-invasive prenatal testing for Down's syndrome: pregnant women's views and likely uptake. *Public Health Genomics*. 2013;20(11):1127–33.
 29. Rouché R. Non-invasive testing, non-invasive counseling. *The Journal of Law, Medicine & Ethics*. 2015;43(2):228–40.
 30. Press N, Browner CH. Why women say yes to prenatal diagnosis. *Soc Sci Med*. 1997;45(7):979–89. **Observational study of prenatal clinical care and the routinization of earlier maternal-fetal serum screening technology found that in some cases meaningful informed consent was eroded by clinical routines that focused on the procedural (blood draw) rather than the substantive (information-gathering) nature of the screening technology**
 31. Suter S. The routinization of prenatal testing. *American Journal of Law & Medicine*. 2002;28(2/3):233–70.
 32. Rapp R. Testing women, testing the fetus: the social impact of amniocentesis in America. Hove: Psychology Press; 1999ac. **Seminal book examining the experiences of women to whom amniocentesis and other diagnostic procedures were first available details the process through with a technology initially used in high-risk pregnancy populations became a common aspect of American prenatal care**
 33. Rothman BK. The tentative pregnancy: how amniocentesis changes the experience of motherhood. New York: Norton; 1993ad. **Foundational book arguing that the routine use of amniocentesis and other diagnostic technologies in pregnancy shapes how women approach pregnancy and bond (or don't) with their fetus and child; in some cases, women may find it hard to fully accept a pregnancy until testing demonstrates the fetus is 'healthy'**
 34. Farrell RM, Agatista PK, Mercer MB, Mitchum A, Coleridge M. The use of noninvasive prenatal testing in obstetric care: educational resources, practice patterns, and barriers reported by a national sample of clinicians. *Prenat Diagn*. 2016;36(6):499–506.
 35. de Jong A, Dondorp WJ, Frints SG, de Die-Smulders CE, de Wert GM. Advances in prenatal screening: the ethical dimension. *Nat Rev Genet*. 2011;12(9):657–63.
 36. de Jong A, Dondorp WJ, de Die-Smulders CE, Frints SG, de Wert GM. Non-invasive prenatal testing: ethical issues explored. *Eur J Hum Genet*. 2010;18(3):272–7.
 37. Gammon B, Allyse M. Decisional regret in women receiving high-risk or inconclusive results from non-invasive prenatal genetic screening. *Prenat Diagn* 2016;36(S1).
 38. Michie M, Kraft SA, Minear MA, Ryan RR, Allyse MA. Informed decision-making about prenatal cfDNA screening: an assessment of written materials. *Ethics, Medicine and Public Health*. 2016;2(3):362–71.
 39. Swaney P, Hardisty E, Sayres L, Wiegand S, Vora N. Attitudes and knowledge of maternal-fetal medicine fellows regarding noninvasive prenatal testing. *J Genet Couns*. 2016;25(1):73–8.
 40. Farrell R, Mercer M, Agatista P, Smith M, Philipson E. It's more than a blood test: patients' perspectives on noninvasive prenatal testing. *Journal of Clinical Medicine*. 2014;3(2):614–31.
 41. Mercer MB, Agatista PK, Farrell RM. What patients are reading about noninvasive prenatal testing: an evaluation of internet content and implications for patient-centered care. *Prenat Diagn*. 2014;34(10):986–93.
 42. Kloza EM, Haddow PK, Halliday JV, O'Brien BM, Lambert-Messerlian GM, Palomaki GE. Evaluation of patient education materials: the example of circulating cell free DNA testing for aneuploidy. *J Genet Couns*. 2015;24(2):259–66.
 43. Farrell RM, Agatista PK, Mercer M, Smith MB. Online direct-to-consumer messages about non-invasive prenatal genetic testing. *Reproductive Biomedicine & Society Online*. 2016;1:88–97.
 44. Benn P, Cuckle H. Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasma. *Prenat Diagn*. 2014;34(8):778–83.
 45. Farrell RM, Nutter B, Agatista PK. Patient-centered prenatal counseling: aligning obstetric healthcare professionals with needs of pregnant women. *Women & Health*. 2015;55(3):280–96.
 46. Jelin AC, Anderson B, Wilkins-Haug L, Schulkin J. Obstetrician and gynecologists' population-based screening practices. *J Matern Fetal Neonatal Med*. 2016;29(6):875–9.
 47. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. *N Engl J Med*. 2015;372:1589–97.
 48. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. *Genet Med*. 2016; doi:10.1038/gim.2016.145. **Evaluates the framework insurance payers use to make coverage decisions for cfDNA; establishes that 8 of 19 payers in the United States were covering cfDNA for average-risk pregnancies where clinical value and updated professional guidelines indicated**
 49. National Society of Genetic Counselors NSGC. 2014 Professional status survey: Available from: <http://nsgc.org/p/cm/ld/fid=68>. Accessed 29 Aug 2014.
 50. Harrison TA, Doyle DL, McGowan C, Cohen L, Repass E, Pfau RB, Brown T. Billing for medical genetics and genetic counseling services: a national survey. *J Genet Couns*. 2010;19(1):38–43.
 51. Begleiter ML, Finley BE. Positive predictive value of cell free DNA analysis. *American Journal of Obstetrics & Gynecology*. 2014;211:81.
 52. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. *Prenat Diagn*. 2013;33(6):542–6.
 53. Heger M. With rapid uptake of noninvasive prenatal screening many question its impact on abortion. *Genomeweb* 2016.
 54. Daley R, Hill M, Chitty LS. Non-invasive prenatal diagnosis: progress and potential. *Arch Dis Child Fetal Neonatal Ed*. 2014; doi:10.1136/archdischild-2013-304828.
 55. Daley B. When baby is due, genetic counselors seen downplaying false alarms. *Boston Globe* 2016.
 56. Radicioni AF, De Marco E, Gianfrilli D, Granato S, Gandini L, Isidori AM, Lenzi A. Strategies and advantages of early diagnosis in Klinefelter's syndrome. *Mol Hum Reprod*. 2010;16(6):434–40.
 57. de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. *Am J Med Genet A*. 2015;167(4):756–67.
 58. Jeon KC, Chen LS, Goodson P. Decision to abort after a prenatal diagnosis of sex chromosome abnormality: a systematic review of the literature. *Genet Med*. 2012;14(1):27–38.
 59. Parens E, Asch A. Disability rights critique of prenatal genetic testing: reflections and recommendations. *Ment Retard Dev Disabil Res Rev*. 2003;9(1):40–7. **Challenges the view that genetic testing is a self-evident good by arguing that with**

- appropriate public support and accommodations, disabling traits need not be detrimental to leading a worthwhile life**
60. Sandelowski M, Jones LC. Healing fictions: stories of choosing in the aftermath of the detection of fetal anomalies. *Soc Sci Med*. 1996;42(3):353–61.
 61. Bernhardt BA, Soucier D, Hanson K, Savage MS, Jackson L, Wapner RJ. Women's experiences receiving abnormal prenatal chromosomal microarray testing results. *Genet Med*. 2013;15:139–45. **Qualitative study finding that for microarray testing it is often difficult for parents to grasp the meaning of results, and some results were very uncertain; extensive pretest and posttest counseling and educational tools required as the numbers of women undergoing such testing increase**
 62. Sandelowski M, Barroso J. The travesty of choosing after positive prenatal diagnosis. *Journal of Obstetric, Gynecologic, & Neonatal Nursing*. 2005;34(3):307–18.
 63. Helm DT, Miranda S, Chedd NA. Prenatal diagnosis of Down syndrome: mothers' reflections on supports needed from diagnosis to birth. *Ment Retard*. 1998;36(1):55–61.
 64. Skotko BG. Prenatally diagnosed Down syndrome: mothers who continued their pregnancies evaluate their health care providers. *Am J Obstet Gynecol*. 2005;192(3):670–7.
 65. Nelson Goff BS, Springer N, Foote LC, Frantz C, Peak M, Tracy C, et al. Receiving the initial Down syndrome diagnosis: a comparison of prenatal and postnatal parent group experiences. *Intellect Dev Disabil*. 2013;51(6):446–57.
 66. Saul RA, Meredith SH. Beyond the genetic diagnosis: providing parents what they want to know. *Pediatr Rev*. 2016;37(7):269–78.
 67. Skotko BG, Levine SP, Goldstein R. Having a son or daughter with Down syndrome: perspectives from mothers and fathers. *Am J Med Genet A*. 2011;155A(10):2335–47.
 68. Skotko BG, Levine SP, Goldstein R. Self-perceptions from people with Down syndrome. *Am J Med Genet A*. 2011;155A(10):2360–9.
 69. Skotko BG, Levine SP, Goldstein R. Having a brother or sister with Down syndrome: perspectives from siblings. *Am J Med Genet A*. 2011;155A(10):2348–59.
 70. Alderson P. Prenatal screening, ethics and Down's syndrome: a literature review. *Nurs Ethics*. 2001;8(4):360–74.
 71. Bittles AH, Glasson EJ. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. *Developmental Medicine & Child Neurology*. 2004;46(4):282–6.
 72. Glasson EJ, Jacques A, Wong K, Bourke J, Leonard H. Improved survival in Down syndrome over the last 60 years and the impact of perinatal factors in recent decades. *J Pediatr*. 2016;169:214–20.
 73. Patterson AR, Robinson LD, Nafatalis EZ, Haley BB, Tomlinson GE. Custodianship of genetic information: clinical challenges and professional responsibility. *J Clin Oncol*. 2005;23(9):2100–4.
 74. Kellogg G, Slatery L, Hudgins L, Ormond K. Attitudes of mothers of children with Down syndrome towards noninvasive prenatal testing. *J Genet Couns*. 2014;23:805–13.
 75. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. *Ultrasound Obstet Gynecol*. 2013;42(1):15–33.
 76. Hall A, Bostanci A, Wright CF. Non-invasive prenatal diagnosis using cell-free fetal DNA technology: applications and implications. *Public Health Genomics*. 2010;13(4):246–55.
 77. Kaplan D. Prenatal screening and its impact on persons with disabilities. *Fetal Diagn Ther*. 1993;8(Suppl. 1):64–9.
 78. Shakespeare TW. Choices, reasons and feelings: prenatal diagnosis as disability dilemma. *ALTER-European Journal of Disability Research/Revue Européenne De Recherche Sur Le Handicap*. 2011;5(1):37–43.
 79. Hickerton CL, Aitken M, Hodgson J, Delatycki MB. "Did you find that out in time?": new life trajectories of parents who choose to continue a pregnancy where a genetic disorder is diagnosed or likely. *Am J Med Genet A*. 2012;158A(2):373–83.
 80. Steinbach RJ, Allyse M, Michie M, Liu EY, Cho MK. This lifetime commitment: public conceptions of disability and noninvasive prenatal genetic screening. *Am J Med Genet A*. 2016;170(2):363–74. **Survey study exploring the variety of views expressed about living with and raising a child with disabilities; most respondents supported the availability of genetic testing despite a range of both positive and negative views of living with disability**
 81. van Schendel RV, Kater-Kuipers A, van Vliet-Lachotzki EH, Dondorp WJ, Cornel MC, Henneman L. What do parents of children with Down syndrome think about non-invasive prenatal testing (NIPT)? *J Genet Couns*. 2016; doi:10.1007/s10897-016-0012-4.
 82. Raz A. "Important to test, important to support": attitudes toward disability rights and prenatal diagnosis among leaders of support groups for genetic disorders in Israel. *Soc Sci Med*. 2004;59(9):1857–66.
 83. Kuppermann M, Nakagawa S, Cohen SR, Dominguez-Pareto I, Shaffer BL, Holloway SD. Attitudes toward prenatal testing and pregnancy termination among a diverse population of parents of children with intellectual disabilities. *Prenat Diagn*. 2011;31(13):1251–8.
 84. Sayres LC, Allyse M, Goodspeed TA, Cho MK. Demographic and experiential correlates of public attitudes towards cell-free fetal DNA screening. *J Genet Couns*. 2014;23:957–67.
 85. Minear M, Alessi S, Michie M, Allyse M, Chandrasakharan S. Where are we now with non-invasive prenatal testing?: a review of current and emerging ethical, legal, and social issues. *Annu Rev Gen Genomics* 2015; In Press.
 86. Flessel M, Goldman S. California prenatal screening program to include noninvasive testing. *Acog.org* 2013; http://www.acog.org/About_ACOG/ACOG_Departments/District_Newsletters/District_IX/September_2013/California_Prenatal_Screening_Program.
 87. Karow J. NIPT continues to take off in 2013 as indications, insurance coverage grow. *GenomeWeb* 2014
 88. Karow J. NIPT insurance coverage for all risk groups expected to pick up after new guidelines, cost studies. *Genomeweb* 2015.
 89. Graf MD, Needham DF, Teed N, Brown T. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers. *Personalized Medicine*. 2013;10(3):235–43.
 90. Prince AE. Prevention for those who can pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease. *J Law Biosci*. 2015;2(2):365–95.
 91. Chitty L, Cameron L, Daley D, Fisher J, Hill M, Jenkins L, et al. RAPID non-invasive prenatal testing (NIPT) evaluation study: a report for the UK national screening committee. 2015. **Results of this study support the addition of NIPT as a contingent test in the United Kingdom's National Health Services Down's syndrome screening pathway.**
 92. Murdoch B, Ravitsky V, Ogbogu U, Ali-Khan S, Bertier G, Birko S, et al. Non-invasive prenatal testing and the unveiling of an impaired translation process. *J Obstet Gynaecol Can*. 2016;39:10–7.
 93. Anderson JM, Rodney P, Reimer-Kirkham S, Browne AJ, Khan KB, Lynam MJ. Inequities in health and healthcare viewed through the ethical lens of critical social justice: contextual knowledge for the global priorities ahead. *Adv Nurs Sci*. 2009;32(4):282–94.
 94. Daniels N. Justice, health, and healthcare. *Am J Bioeth*. 2001;1(2):2–16.
 95. Bryant AS, Worjolah A, Caughey AB, Washington AE. Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants. *Am J Obstet Gynecol*. 2010;202(4):335–43.

96. Smith CE, Fullerton SM, Dookeran KA, Hampel H, Tin A, Maruthur NM, et al. Using genetic technologies to reduce, rather than widen, health disparities. *Health Aff.* 2016;35(8):1367–73.
97. Markens S. ‘I’m not sure if they speak to everyone about this option’: analyzing disparate access to and use of genetic health services in the US from the perspective of genetic counselors. *Critical Public Health.* 2016;16:1–14.
98. Bryant AS, Worjolah A, Caughey AB, Washington AE. Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants. *Am J Obstet Gynecol.* 2010;202(4):335–43. **Examines the variety of factors that lead to disparate health outcomes in obstetric care based on racial and ethnic differences and suggests root causes and potential interventions to improve outcomes**
99. Agarwal A, Sayres LC, Cho MK, Cook-Deegan R, Chandrasekharan S. Commercial landscape of noninvasive prenatal testing in the United States. *Prenat Diagn.* 2013;33(6):521–31. **Provides an overview of the patent and intellectual property claims at issue in the cfDNA market**
100. UPDATE: Appeals court upholds invalidity of sequenom patent | genomeweb; Available from: <https://www.genomeweb.com/business-news/update-appeals-court-upholds-invalidity-sequenom-patent>. Accessed 27 Oct 2016.
101. FDA to finalize LDT guidance amid uncertainty on number of genetic tests impacted | genomeweb; Available from: <https://www.genomeweb.com/molecular-diagnostics/fda-finalize-ldt-guidance-amid-uncertainty-number-genetic-tests-impacted>. Accessed 28 Oct 2016.
102. Collins L, Ewing F, Fernandes, JS, Lin J, Wu LX. Laboratory developed tests emerging in FDA Regulation. *The National Law Review* 2016. Available at: <http://www.natlawreview.com/article/laboratory-developed-tests-emerging-fda-regulation>. Accessed 31 Oct 2016.
103. Allyse M, Sayres C, King S, Norton E, Cho K. Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US context. *Hum Reprod.* 2012;27(11):3123–31.
104. Abortion bans in cases of sex or race selection or genetic anomaly | Guttmacher Institute; Available from: <https://www.guttmacher.org/state-policy/explore/abortion-bans-cases-sex-or-race-selection-or-genetic-anomaly>. Accessed 31 Oct 2016.
105. Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S, Atrash HK. Risk factors for legal induced abortion-related mortality in the United States. *Obstet Gynecol.* 2004;103(4):729–37.
106. Kelly N. *Indiana journal gazette*; Available from: <http://www.journalgazette.net/news/local/indiana/Judge-strikes-down-Indiana-abortion-law-13867401>. Accessed 31 Oct 2016.
107. Pergament D, Iljic K. The legal past, present and future of prenatal genetic testing: professional liability and other legal challenges affecting patient access to services. *Journal of Clinical Medicine.* 2014;3(4):1437–65.
108. Gammon BL, Kraft SA, Michie M, Allyse M. I think we’ve got too many tests!: prenatal providers reflections on ethical and clinical challenges in the practice integration of cell-free DNA screening. *Ethics, Medicine and Public Health.* 2016;2(3):334–42.
109. Marchant GE, Lindor RA. Personalized medicine and genetic malpractice. *Genet Med.* 2013;15(12):921–2.
110. Prenatal assessment of genomes and exomes (PAGE) | Sanger institute; Available from: <http://www.sanger.ac.uk/science/collaboration/prenatal-assessment-genomes-and-exomes-page>. Accessed 14 Nov 2016.
111. Chiu RW. Hunting for the signatures of cancer by plasma DNA sequencing. *Pathology.* 2016;48:S30.
112. Hudcová I, Chiu RW. Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA. *Best Pract Res Clin Obstet Gynaecol* 2016.
113. Christianson A, Howson CP, Modell B. March of dimes: global report on birth defects, the hidden toll of dying and disabled children. 2005.
114. Jain CV, Kadam L, van Dijk M, Kohan-Ghadr H-R, Kilburn BA, Hartman C, et al. Fetal genome profiling at 5 weeks of gestation after noninvasive isolation of trophoblast cells from the endocervical canal. *Sci Transl Med.* 2016;8(363):363re4.
115. Bartesaghi R, Haydar TF, Delabar JM, Dierssen M, Martínez-Cué C, Bianchi DW. New perspectives for the rescue of cognitive disability in Down syndrome. *J Neurosci.* 2015;35(41):13843–52.
116. Allyse M, Minear MA, Berson E, Sridhar S, Rote M, Hung A, Chandrasekharan S. Non-invasive prenatal testing: a review of international implementation and challenges. *International Journal of Women’s Health.* 2015;7:113.
117. Boardman FK. The expressivist objection to prenatal testing: the experiences of families living with genetic disease. *Soc Sci Med.* 2014;107:18–25.
118. Kittay EF, Kittay L. On the expressivity and ethics of selective abortion for disability: conversations with my son. *Prenatal testing and disability rights* 2000:165–95.
119. Shakespeare T. Choices and rights: eugenics, genetics and disability equality. *Disability & Society.* 1998;13(5):665–81.
120. Steinbach RJ, Allyse M, Michie M, Liu EY, Cho MK. “This lifetime commitment”: public conceptions of disability and noninvasive prenatal genetic screening. *Am. J. Med. Genet.* 2015; 170(2).
121. Blumenshine P, Egerter S, Barclay CJ, Cubbin C, Braveman PA. Socioeconomic disparities in adverse birth outcomes: a systematic review. *Am J Prev Med.* 2010;39(3):263–72.
122. MacDorman MF. Race and ethnic disparities in fetal mortality, preterm birth, and infant mortality in the United States: an overview. *Semin Perinatol.* 2011;35(4):200–8.